Certolizumab pegol for the treatment of Crohn's disease.
about
Pharmacologic therapy for inflammatory bowel disease refractory to steroidsMucosal healing and deep remission: what does it mean?Efficacy and safety of certolizumab pegol for Crohn's disease: a systematic review and meta-analysis.Indicators of suboptimal biologic therapy over time in patients with ulcerative colitis and Crohn's disease in the United StatesMeasuring patients' satisfaction with their anti-TNF treatment in severe Crohn's disease: scoring and psychometric validation of the Satisfaction for PAtients in Crohn's diseasE Questionnaire (SPACE-Q(©)).Update on the safety profile of certolizumab pegol in rheumatoid arthritis: an integrated analysis from clinical trials.From stealthy polymersomes and filomicelles to "self" Peptide-nanoparticles for cancer therapyThe incidence of tuberculosis in patients treated with certolizumab pegol across indications: impact of baseline skin test results, more stringent screening criteria and geographic region.Surgical treatment of anorectal crohn disease.Scintigraphic detection of TNF-driven inflammation by radiolabelled certolizumab pegol in patients with rheumatoid arthritis and spondyloarthritis.Acid-Sensitive Sheddable PEGylated PLGA Nanoparticles Increase the Delivery of TNF-α siRNA in Chronic Inflammation Sites.Apoptosis and the FLIP and NF-kappa B proteins as pharmacodynamic criteria for biosimilar TNF-alpha antagonists.Evaluation of pharmacokinetics and pharmacodynamics and clinical efficacy of certolizumab pegol for Crohn's disease.Certolizumab pegol for the treatment of psoriatic arthritis.Dose escalation of biologics in Crohn's disease: critical review of observational studies.Adalimumab for maintenance therapy for one year in Crohn's disease: results of a Latin American single-center observational study.Optimization of biologic therapy in Crohn's disease.Approach to Optimize Anti-TNF-α Therapy in Patients With IBD.Precision Medicine in Inflammatory Bowel Diseases.Improving the sensitivity and specificity of a bioanalytical assay for the measurement of certolizumab pegol.Medical and surgical management of perianal Crohn's disease.
P2860
Q26796415-545D7408-7CA2-49F6-B4D9-4C5C45F90014Q26852447-10606EF5-FACE-46CC-9F6B-57BD29F39132Q30486142-469CA379-B020-4FAE-8ECD-55A5B7F3112FQ33584629-2C147251-50A3-407F-8B18-90A5D87A6E5FQ34671143-DD54C089-FE48-4B90-B352-BE4D2711DF8FQ34818636-985339AE-C8D6-46D6-8704-410C31CF0B4DQ35295381-3FF913C4-4E96-4A8F-82C1-D758AB45E4E2Q36183786-BA30135A-D5D0-4EED-BBF1-CD7466F865DAQ37007911-EE572A42-1FA9-45FD-889F-B9169E4745B4Q37063563-32E65A8F-FE16-4611-BFAA-862DB0DE2BFEQ37672324-C43DEA95-E20A-4EB4-87FA-5EAB1249A247Q38239111-ACD97896-9933-416E-AAF1-50F46C248D84Q38317338-CB775E8F-688E-4FDF-84F4-DDCABE1E0658Q38344194-65F6FA28-02C6-46CC-9646-779387EB4FABQ39326057-5C8B53C6-DC52-41C1-ABF1-F49DACAFE7C8Q43515258-616CD74C-9E32-430C-9661-4AC51B40F1CAQ47389870-6DB6DAD8-9454-4171-A21F-8BAEC0EFE65BQ50713607-BC4CDC57-7269-4C36-88C2-51CE75C5601EQ51828636-33FB7789-8A3B-42D0-9DB0-273C4F04D962Q53164680-F5FA2A2D-EA5D-40D2-9BF9-1CC4C6E858AEQ55103450-6EE9A14D-3B9A-4342-8814-4C908D380ED4
P2860
Certolizumab pegol for the treatment of Crohn's disease.
description
2011 nî lūn-bûn
@nan
2011 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Certolizumab pegol for the treatment of Crohn's disease.
@ast
Certolizumab pegol for the treatment of Crohn's disease.
@en
type
label
Certolizumab pegol for the treatment of Crohn's disease.
@ast
Certolizumab pegol for the treatment of Crohn's disease.
@en
prefLabel
Certolizumab pegol for the treatment of Crohn's disease.
@ast
Certolizumab pegol for the treatment of Crohn's disease.
@en
P2860
P356
P1476
Certolizumab pegol for the treatment of Crohn's disease.
@en
P2093
Stefan Schreiber
P2860
P304
P356
10.1177/1756283X11413315
P577
2011-11-01T00:00:00Z